logo

Barbara Burtness, MD

Barbara Burtness, MD

Oncology New Haven, CT

Co-Leader Developmental Therapeutics

Office Address

Office Map
  • 333 Cedar St
    New Haven, CT 06520
    Phone: (203) 737-7636

Dr. Burtness's Clinical Specialties & Interests

  • Oncology: Interventional

Dr. Burtness's Faculty Appointments & Work History

  • External ReviewerNational Cancer Institute
  • Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine; Co-Leader, Developmental Therapeutics Program, Director of Head and Neck Cancer Clinical Research Program, Yale Cancer CenterYale University School of Medicine
    New Haven, CT
    Director of Head and Neck Cancer Research; Co-Leader, Developmental Therapeutics Program
  • Co-LeaderHead and Neck Service Line
    AE
  • Ad hoc ReviewerMedical Research Council of South Africa
  • ProfessorFox Chase Cancer Center
    AE
    Co-Leader, Developmental Therapeutics Program (2010-present); Head of Translational Research (2010-present); Head of Translational Research (2010-present); Associate Director, Clinical Research (2011-present)
  • Ad hoc ReviewerDutch Cancer Society
  • Interim DirectorFox Chase Cancer Center
    Co-director, Signaling in Head and Neck Cancer, Keystone Program-in-Development (2008-2009); Chief, Head and Neck Oncology Section (2008-); Co-leader, Head and Neck Working Group (2008-); Senior Member, Department of Medical Oncology and Developmental Therapeutics Program (2008-)
  • ReviewerCanadian Institutes of Health Research
  • ReviewerNational Institutes of Health., Office for Protection from Research Risks
  • Attending PhysicianYale-New Haven Hospital
  • Attending PhysicianWest Haven VA Medical Center
  • Instructor.Yale University School of Medicine
    New Haven, CT
    Assistant Professor, Section of Medical Oncology (1993-1999); Assistant Professor, Clinician-Scholar Track (1999-2005); Director, Gastrointestinal Oncology Unit (1998-2005); 1998-2003 Director, Breast Oncology Unit (1998-2003)

Dr. Burtness's Education & Medical Training

  • Memorial Sloan-KetteringMemorial Sloan-KetteringFellowship, Hematology/Oncology
  • Yale-New Haven HospitalYale-New Haven HospitalResidency, Internal Medicine
  • Yale-New Haven HospitalYale-New Haven HospitalInternship, Internal Medicine
  • SUNY Stony Brook Hlth Sci CtrStony Brook University School of MedicineMedical School
  • Bryn Mawr CollegeBryn Mawr CollegeOther Training, A.B, Biology, Honors

Dr. Burtness's Certifications & Licensure

  • PA State Medical LicensePA State Medical License2005 - 2014
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine, 1989
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology, 1993

Dr. Burtness's Clinical Trials

Dr. Burtness's Publications & Presentations

PubMed | Citations by Web of Science®

Journal Articles

  • Images in Medicine: Cetuximab-associated acneiform rash.Moss J and B Burtness, N Engl J Med 353:e17.
  • Oxaliplatin induces a delayed immune hemolytic anemia: A case report and review of the literature.Noronha V, B Burtness, J Murren, TP Duffy., Clin Colorectal Ca 5:283-286
  • Bimodal population or pathologist artifact? Correspondence.4. Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B, J Clin Oncol; 25:2487-8.

Books/Book Chapters

  • Novel targets in pancreatic cancer: focus on future paths to therapy.
    Cohen S and B Burtness.
    Editors: .
  • Clinical use in colorectal cancer of monoclonal antibodies to the epidermal growth factor receptor.
    Burtness B
    Editors: .
  • HER signaling in pancreatic cancer.
    Burtness B
    Editors: .
  • Register to See 50 More...

Abstracts/Posters

  • EGFR inhibition in head and neck cancer – more insights but more questionsForastiere AA and BA Burtness., J Clin Oncol 25:2152-5
  • Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer.Shanbhag S and B Burtness, Eur J Clin Med Oncol
  • A 5 year follow up of an expanded phase II study evaluating adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high-risk breast cancer.Abu-Khalaf M, S Windsor, K Ebisu, S Salikooti, G Chung, M DiGiovanna, B Haffty, M Abrams, L Farber, AD Hsu, M Reiss, D Zelterman, B Burtness., Oncology 69:372-383.
  • Register to See 24 More...

Lectures

  • Setting Up and Running Multicenter Randomized Trials.American Head and Neck Society Annual Meeting, Toronto.
  • Integrating Targeted Therapies into Standard Treatments, Meet the Professor Session.American Head and Neck Society Annual Meeting,Toronto.
  • Esophagogastric Discussion: Trials in Unselected Patients, Gastrointestinal (Non-colorectal) Oral Abstract Session.American Society of Clinical Oncology Annual Meeting, Chicago.
  • Register to See 32 More...

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Burtness's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV